Good VDO of Fatal Overdoses with Effexor - News Report
Not some time past, I presented the story. Useful. these days i'm pleased to gift Video on Effexor Side Effects. i need it to block my sisters. and therefore the public. information that is useful. along with your friends. Fatal Overdoses with Effexor - News Report, that I have seen this as an outstanding contribution. VDO is the knowledge. The End. Judgment in the view. Fatal Overdoses with Effexor - News Report Video Clips. Duration : 1.40 Mins.Courtesy of www.medstores.net Effexor (Venlafaxine) is an arylalkanolamine serotonin-norepinephrine reuptake inhibitor (SNRI). It has a similar chemical structure to the opioid derivative tramadol, and has the tertiary amine functional group necessary for ยต-opioid receptor recognition (cf. lefetamine), though it is unknown whether it has an opioid agonist effect. It is surprisingly effective in treating depression in heroin and other opioid addicts compared to all other conventional antidepressants. First introduced by Wyeth in 1993, now marketed by Pfizer, it is licensed for the treatment of major depressive disorder (MDD), as a treatment for generalized anxiety disorder, and comorbid indications in certain anxiety disorders with depression. In 2007, venlafaxine was the sixth most commonly prescribed antidepressant on the US retail market, with 17.2 million prescriptions. In children and adolescents, venlafaxine (like other antidepressants) has a potential to increase suicidal thoughts, attempts and events of self-harm Multiple double blind studies show venlafaxine's effectiveness in treating depression. Venlafaxine has similar efficacy to the tricyclic antidepressants amitriptyline (Elavil) and imipramine, and is better tolerated than amitriptyline. Its efficacy is similar to or better than sertraline (Zoloft) and fluoxetine (Prozac), depending on the criteria and rating scales used. Higher doses of venlafaxine are more effective, and more patients achieved remission or ...
We'll get this from me. I am pleased to present the information.
No comments:
Post a Comment